Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 3/20 | 0.49 |
| ▸ | DAO | P14920 | 5/20 | 0.45 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | SLC5A1 | P13866 | 2/20 | 0.41 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2773403 | 0.81 | PIK3CG (0.46) | PIK3CGADRA1DADRA1AADRA1BTAAR1 | |
| SCHEMBL1383308 | 0.80 | HRH3 (0.45) | CYP3A4MAPTALDH1A1CYP2C9PKM | |
| SCHEMBL5164873 | 0.80 | KMT2A (0.57) | PIK3CGMAPTALDH1A1TSHRMAPK1 | |
| SCHEMBL2772180 | 0.77 | ALDH1A1 (0.49) | PIK3CGDAOSLC5A1SLC5A2ALDH1A1 | |
| SCHEMBL5145629 | 0.77 | GSK3A (0.59) | PIK3CGDAOMAPTALDH1A1TSHR | |
| SCHEMBL1379949 | 0.75 | MAPT (0.37) | PIK3CGCYP3A4MAPTALDH1A1CYP2C9 | |
| Iodide SCHEMBL2408901 | 0.73 | MAPT (0.36) | PIK3CGCYP3A4MAPTALDH1A1CYP2C9 | |
| SCHEMBL2771184 | 0.73 | ALDH1A1 (0.46) | PIK3CGSLC5A1SLC5A2CYP3A4ALDH1A1 | |
| SCHEMBL2442362 | 0.72 | NAAA (0.43) | PIK3CGTAAR1CYP3A4MAPTALDH1A1 | |
| SCHEMBL7957008 | 0.71 | ADRA1D (0.62) | DAOADRA1DADRA1AADRA1BMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1590321-B1 | ARYL ALKYL CARBAMATE DERIVATIVES PRODUCTION AND USE THEREOF IN THERAPY | SANOFI AVENTIS (FR) | 2010-04-28 | — | — | EP | disclosed |
| US-7632850-B2 | 2-amino-2-oxoethyl 1-(4'-fluoro-1,1'-biphenyl-4-yl)cyclopropylmethylcarbamate and 2-(methylamino)-2-oxoethyl 1-(4'-fluoro-1,1'-biphenyl-4-yl)cyclopropylmethylcarbamate; fatty acid amide (FAAH) hyrdrolase inhibitors; analgesics; neuropathic pain;psychological disorders; anticarcinogenic agents; AIDS | SANOFI-AVENTIS (FR) | 2009-12-15 | — | — | US | disclosed |
| US-20060014830-A1 | Arylalkylcarbamate derivatives production and use thereof in therapy | SANOFI-AVENTIS (FR) | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014830-A1 | Arylalkylcarbamate derivatives production and use thereof in therapy | CBR3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C5 | PIK3CG 4177/4885DAO 1104/4885ADRA1D 1187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.